title: Management of small renal masses: a review.
abstract: BACKGROUND
  Recently, small renal masses (SRMs) (< or =4 cm) are found more frequently, especially in the elderly and co-morbid patients. Standard treatment for SRMs is nephron-sparing surgery (NSS). New techniques like energy ablation and surveillance have been introduced.
  
  
  METHODS
  Overview of treatment options for SRMs, based mainly on the meta-analyses available for NSS, cryoablation, radio-frequency ablation (RFA), and surveillance.
  
  
  RESULTS
  NSS for SRMs is the standard therapy with excellent cancer-specific survival rates up to 97%. Cryoablation was mainly performed laparoscopically, and RFA mainly percutaneously. Pretreatment biopsies were used frequently for cryoablation (80%) and less frequently for RFA (50%). Primary failure rate for cryoablation was 4.8% and for RFA 13%. Major complication rates for both procedures are around 5%. Based on 6-month post-ablative biopsies, non-contrast enhancement seems to be an effective surrogate marker after cryoablation, but not after RFA. Follow-up after energy ablation is too short to draw final conclusion. Data on surveillance are based on small, retrospective data with insufficient follow-up. Growth patterns during follow-up do not correlate with the underlying tumour entity.
  
  
  CONCLUSIONS
  Standard therapy for SRMs is still NSS. Energy ablation should be reserved for the elderly patients with co-morbidities and surveillance for the elderly and infirm patients.
authors.affiliation: Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. mRemzi@gmx.at
authors.forename: Mesut
authors.initials: M
authors.lastname: Remzi
authors.forename: Elchin
authors.initials: E
authors.lastname: Javadli
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ozsoy
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle; D017115:Catheter Ablation / Q000379:methods; D003452:Cryosurgery / Q000379:methods; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D053685:Laser Therapy / Q000379:methods; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods*; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D047368:Tumor Burden; D018084:Ultrasonography, Interventional / Q000379:methods